AP9901581A0 - Therapeutic combinations for musculoskeletal frailty. - Google Patents
Therapeutic combinations for musculoskeletal frailty.Info
- Publication number
- AP9901581A0 AP9901581A0 APAP/P/1999/001581A AP9901581A AP9901581A0 AP 9901581 A0 AP9901581 A0 AP 9901581A0 AP 9901581 A AP9901581 A AP 9901581A AP 9901581 A0 AP9901581 A0 AP 9901581A0
- Authority
- AP
- ARIPO
- Prior art keywords
- compositions
- frailty
- pyridin
- oxo
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
This invention is directed to pharmaceuticl combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-n-(1(r)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-(3-oxo-3a(r)-pyridin-2-ylmethyl)-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethyl)-2-methyl-propionamide or a pharmaceutically acceptable salth thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscl mass.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP9901581A0 true AP9901581A0 (en) | 1999-06-30 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1999/001581A AP9901581A0 (en) | 1998-06-16 | 1999-06-10 | Therapeutic combinations for musculoskeletal frailty. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (en) |
| JP (1) | JP2002518328A (en) |
| KR (1) | KR20010052817A (en) |
| CN (1) | CN1305378A (en) |
| AP (1) | AP9901581A0 (en) |
| AR (1) | AR018868A1 (en) |
| AU (1) | AU3342099A (en) |
| BG (1) | BG105128A (en) |
| BR (1) | BR9911357A (en) |
| CA (1) | CA2335112A1 (en) |
| CO (1) | CO5070586A1 (en) |
| EA (1) | EA200001189A1 (en) |
| GT (1) | GT199900083A (en) |
| HR (1) | HRP20000857A2 (en) |
| HU (1) | HUP0102395A2 (en) |
| ID (1) | ID26726A (en) |
| IL (1) | IL139587A0 (en) |
| IS (1) | IS5727A (en) |
| MA (1) | MA26648A1 (en) |
| NO (1) | NO20006381D0 (en) |
| OA (1) | OA11569A (en) |
| PA (1) | PA8472101A1 (en) |
| PE (1) | PE20000633A1 (en) |
| PL (1) | PL345064A1 (en) |
| SK (1) | SK18902000A3 (en) |
| TN (1) | TNSN99118A1 (en) |
| UY (1) | UY25557A1 (en) |
| WO (1) | WO1999065488A1 (en) |
| ZA (1) | ZA993973B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| AU2001276608A1 (en) * | 2000-08-30 | 2002-03-13 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| JP2005515988A (en) * | 2001-11-29 | 2005-06-02 | ジーティーエックス・インコーポレイテッド | Prevention and treatment of androgen deficiency causing osteoporosis |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| EP2644618B1 (en) | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-05-03 EA EA200001189A patent/EA200001189A1/en unknown
- 1999-05-03 PL PL99345064A patent/PL345064A1/en unknown
- 1999-05-03 ID IDW20002604A patent/ID26726A/en unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/en not_active Application Discontinuation
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/en unknown
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/en unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 IL IL13958799A patent/IL139587A0/en unknown
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/en active Pending
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/en not_active Application Discontinuation
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Application Discontinuation
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 CN CN99807381A patent/CN1305378A/en active Pending
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/en unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 UY UY25557A patent/UY25557A1/en not_active Application Discontinuation
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/en not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/en unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/en unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/en not_active Application Discontinuation
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/en unknown
- 1999-06-15 MA MA25622A patent/MA26648A1/en unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/en unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/en unknown
- 2000-12-14 NO NO20006381A patent/NO20006381D0/en not_active Application Discontinuation
- 2000-12-14 HR HR20000857A patent/HRP20000857A2/en not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL139587A0 (en) | 2002-02-10 |
| CA2335112A1 (en) | 1999-12-23 |
| PA8472101A1 (en) | 2000-09-29 |
| NO20006381L (en) | 2000-12-14 |
| JP2002518328A (en) | 2002-06-25 |
| CN1305378A (en) | 2001-07-25 |
| NO20006381D0 (en) | 2000-12-14 |
| AR018868A1 (en) | 2001-12-12 |
| HRP20000857A2 (en) | 2001-10-31 |
| GT199900083A (en) | 2000-12-05 |
| MA26648A1 (en) | 2004-12-20 |
| HUP0102395A2 (en) | 2001-11-28 |
| EA200001189A1 (en) | 2001-06-25 |
| KR20010052817A (en) | 2001-06-25 |
| SK18902000A3 (en) | 2001-12-03 |
| WO1999065488A1 (en) | 1999-12-23 |
| TNSN99118A1 (en) | 2005-11-10 |
| ZA993973B (en) | 2000-12-15 |
| ID26726A (en) | 2001-02-01 |
| UY25557A1 (en) | 2001-01-31 |
| PE20000633A1 (en) | 2000-07-26 |
| CO5070586A1 (en) | 2001-08-28 |
| EP1085867A1 (en) | 2001-03-28 |
| IS5727A (en) | 2000-11-24 |
| PL345064A1 (en) | 2001-11-19 |
| BG105128A (en) | 2001-11-30 |
| BR9911357A (en) | 2001-03-13 |
| AU3342099A (en) | 2000-01-05 |
| OA11569A (en) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1222195E (en) | NEW COMPOUNDS OF TIAZOLO (4,5-D) PYRIMIDINE | |
| LU91710I2 (en) | Pazopanib, optionally in the form of a pharmaceutically acceptable salt or solvate thereof | |
| EE9900539A (en) | New compounds | |
| EA200400735A1 (en) | 3-β-D-RIBOFURANOSYLTIAZOLO [4,5-d] Pyrimidine Nucleoside and Their Uses | |
| WO2000021926A3 (en) | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | |
| ZA9810735B (en) | Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use | |
| AP9901581A0 (en) | Therapeutic combinations for musculoskeletal frailty. | |
| AP9901582A0 (en) | Combination therapy for musculoskeletal frailty. | |
| YU75800A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| NZ504051A (en) | Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| WO2002059109A3 (en) | Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| AU2001265248A1 (en) | Measurement of the therapeutic dose for bone marrow ablation therapy |